77 related articles for article (PubMed ID: 12111648)
1. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
Virchis A; Ganeshaguru K; Hart S; Jones D; Fletcher L; Wright F; Wickremasinghe R; Man A; Csermak K; Meyer T; Fabbro D; Champain K; Yap A; Prentice HG; Mehta A
Hematol J; 2002; 3(3):131-6. PubMed ID: 12111648
[TBL] [Abstract][Full Text] [Related]
2. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Propper DJ; McDonald AC; Man A; Thavasu P; Balkwill F; Braybrooke JP; Caponigro F; Graf P; Dutreix C; Blackie R; Kaye SB; Ganesan TS; Talbot DC; Harris AL; Twelves C
J Clin Oncol; 2001 Mar; 19(5):1485-92. PubMed ID: 11230495
[TBL] [Abstract][Full Text] [Related]
4. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
Thavasu P; Propper D; McDonald A; Dobbs N; Ganesan T; Talbot D; Braybrook J; Caponigro F; Hutchison C; Twelves C; Man A; Fabbro D; Harris A; Balkwill F
Cancer Res; 1999 Aug; 59(16):3980-4. PubMed ID: 10463595
[TBL] [Abstract][Full Text] [Related]
5. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PKCalpha activation in human bone and soft tissue sarcoma cells by the selective PKC inhibitor PKC412.
Kawamoto T; Akisue T; Kishimoto K; Hara H; Imabori M; Fujimoto T; Kurosaka M; Hitora T; Kawaguchi Y; Yamamoto T
Anticancer Res; 2008; 28(2A):825-32. PubMed ID: 18507025
[TBL] [Abstract][Full Text] [Related]
7. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
[TBL] [Abstract][Full Text] [Related]
8. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
9. Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.
Si MS; Reitz BA; Borie DC
Int Immunopharmacol; 2005 Jul; 5(7-8):1141-9. PubMed ID: 15914319
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
11. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
[TBL] [Abstract][Full Text] [Related]
12. PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.7 macrophages.
Miyatake K; Inoue H; Hashimoto K; Takaku H; Takata Y; Nakano S; Yasui N; Itakura M
Biochem Biophys Res Commun; 2007 Aug; 360(1):115-21. PubMed ID: 17585881
[TBL] [Abstract][Full Text] [Related]
13. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
[TBL] [Abstract][Full Text] [Related]
14. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
[TBL] [Abstract][Full Text] [Related]
15. A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography.
Illmer T; Thiede HM; Thiede C; Bornhäuser M; Schaich M; Schleyer E; Ehninger G
J Pharmacol Toxicol Methods; 2007; 56(1):23-7. PubMed ID: 17395497
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Hebb J; Assouline S; Rousseau C; Desjardins P; Caplan S; Egorin MJ; Amrein L; Aloyz R; Panasci L
Cancer Chemother Pharmacol; 2011 Sep; 68(3):643-51. PubMed ID: 21120481
[TBL] [Abstract][Full Text] [Related]
17. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Furukawa Y; Vu HA; Akutsu M; Odgerel T; Izumi T; Tsunoda S; Matsuo Y; Kirito K; Sato Y; Mano H; Kano Y
Leukemia; 2007 May; 21(5):1005-14. PubMed ID: 17330105
[TBL] [Abstract][Full Text] [Related]
18. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of oral topotecan in hematological malignancies.
Beran M; O'Brien S; Thomas DA; Tran HT; Cortes-Franco JE; Giles F; Estey E; Kantarjian HM
Clin Cancer Res; 2003 Sep; 9(11):4084-91. PubMed ID: 14519630
[TBL] [Abstract][Full Text] [Related]
20. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
